Hospital General Unviersitario de Alicante

Alicante 3010

1 studies enrolling now · 8 studies all time

What they study most

Atopic Dermatitis, B-Cell Malignancies, Chronic Lymphocytic Leukemia, Essential Thrombocythemia, Follicular Lymphoma, Marginal Zone Lymphoma, Myelofibrosis, Non Hodgkin Lymphoma, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis, Prurigo

Studies at this site

• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis — Running, not enrolling
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) — Stopped early
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early